T-Bird Pharma Inc (TBQBF) 0.3479 $TBQBF
T-Bird Pharma Inc. Announces Funding from the Government of Canada
CNW Group - Wed May 13, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate and sell marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it will receive funding through NRC-IRAP (National Research Council of Canada-IRAP) for research and development work related to the Company's strains of medical cannabis.
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Health Canada License Renewal including full Authorization to Sell
CNW Group - Thu May 07, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company", a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that its wholly owned subsidiary Thunderbird Biomedical Inc. has received a notice from Health Canada dated May 6, 2015 confirming the renewal of its production license, and including the expansion of its license to include full authorization to commence medical marijuana sales.
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences
CNW Group - Fri Apr 24, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company", a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it, together with certain of its shareholders, has closed the transaction announced on March 11, 2015 with Medna Biosciences Inc. ("Medna". Medna has acquired (the "Escrow Transfer" a total of 20,156,790 common shares of T-Bird (45% of the Company's issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares have been transferred within the escrow and remain bound by those terms and conditions. The Escrow Transfer has been approved by the TSX Venture Exchange.
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Health Canada Submission for Second Production Facility
CNW Group - Fri Apr 10, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company", a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it has submitted an application to Health Canada for a second medical marijuana production facility in Victoria, BC.
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval
CNW Group - Tue Mar 31, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company", a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it has received notice from The Corporation of the District of Saanich confirming the final rezoning approval of the Company's premises which now allows for commercial distribution of medical marijuana under the MMPR.
TPI.VN: 0.415 (-0.025)
IIROC Trade Resumption - T-Bird Pharma Inc.
Newsfile Corp - Thu Mar 12, 7:11AM CDT
Trading resumes in:
IIROC Trading Resumption - TPI
CNW Group - Thu Mar 12, 7:07AM CDT
Trading resumes in:
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Partnership with Medna Biosciences Inc.
CNW Group - Wed Mar 11, 3:15PM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company", a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it, together with certain of its shareholders, has entered into an agreement with Medna Biosciences Inc. ("Medna" whereby Medna will acquire (the "Escrow Transfer" a total of 20,156,790 common shares of T-Bird (45% of the Company's issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares will be transferred within escrow and remain bound by those terms and conditions. The Escrow Transfer is subject to TSX-V approval.
INO: 8.10 (+0.13), TPI.VN: 0.415 (-0.025)
IIROC Trade Halt - T-Bird Pharma Inc.
Newsfile Corp - Wed Mar 11, 11:55AM CDT
The following issues have been halted by IIROC:
IIROC Trading Halt - TPI
CNW Group - Wed Mar 11, 11:52AM CDT
The following issues have been halted by IIROC:
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces License Renewal from Health Canada
CNW Group - Tue Feb 10, 6:00AM CST
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company", a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", wishes to announce that its wholly owned subsidiary Thunderbird Biomedical Inc. has received a notice from Health Canada dated February 6, 2015 confirming the renewal of its production license at the Company's production facility in Saanich, British Columbia.
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Appoints Sandy Pratt as Chief Financial Officer
CNW Group - Tue Jan 27, 6:00AM CST
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company", a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", wishes to announce that Sandra (Sandy) Pratt has joined the Company as Chief Financial Officer, replacing Chris Taylor who has stepped down to return to his private practice. Taylor will remain involved with the Company at the Board level by continuing on as Corporate Secretary and operationally as an RPIC and consultant. "Chris' background in our history and operations is valuable so we are very pleased to see that he has agreed to remain involved with the Company at the Board level" noted David Raffa, Chairman of the Board. Added Raffa, "the addition of Sandy to our team represents another step in increasing the operational experience within our company as we commercialize our operation. We are very pleased she has agreed to join our team."
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Appoints Dr. Bin Huang as Chief Executive Officer
CNW Group - Mon Jan 19, 5:00AM CST
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company", a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", wishes to announce that Robert Gagnon has stepped down as CEO and Board member. Dr. Bin Huang, who joined the Company last Fall as President and Chief Operating Officer, has been appointed CEO in his place. Noted Gagnon, "Now that the Company is launched and we have brought in professional management, it is time for me to step aside. I am confident in Dr. Huang and the team she is building and pleased that she has agreed to lead the next stage of our growth." Gagnon will be retained by the Company as a consultant for a period of one year.
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Funding from the Government of Canada
CNW Group - Wed May 13, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate and sell marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it will receive funding through NRC-IRAP (National Research Council of Canada-IRAP) for research and development work related to the Company's strains of medical cannabis. TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Health Canada License Renewal including full Authorization to Sell
CNW Group - Thu May 07, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that its wholly owned subsidiary Thunderbird Biomedical Inc. has received a notice from Health Canada dated May 6, 2015 confirming the renewal of its production license, and including the expansion of its license to include full authorization to commence medical marijuana sales. TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences
CNW Group - Fri Apr 24, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it, together with certain of its shareholders, has closed the transaction announced on March 11, 2015 with Medna Biosciences Inc. ("Medna". Medna has acquired (the "Escrow Transfer" a total of 20,156,790 common shares of T-Bird (45% of the Company's issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares have been transferred within the escrow and remain bound by those terms and conditions. The Escrow Transfer has been approved by the TSX Venture Exchange. TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Health Canada Submission for Second Production Facility
CNW Group - Fri Apr 10, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it has submitted an application to Health Canada for a second medical marijuana production facility in Victoria, BC. TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval
CNW Group - Tue Mar 31, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it has received notice from The Corporation of the District of Saanich confirming the final rezoning approval of the Company's premises which now allows for commercial distribution of medical marijuana under the MMPR. TPI.VN: 0.415 (-0.025)
IIROC Trade Resumption - T-Bird Pharma Inc.
Newsfile Corp - Thu Mar 12, 7:11AM CDT
Trading resumes in:
IIROC Trading Resumption - TPI
CNW Group - Thu Mar 12, 7:07AM CDT
Trading resumes in:
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces Partnership with Medna Biosciences Inc.
CNW Group - Wed Mar 11, 3:15PM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", is pleased to announce that it, together with certain of its shareholders, has entered into an agreement with Medna Biosciences Inc. ("Medna" whereby Medna will acquire (the "Escrow Transfer" a total of 20,156,790 common shares of T-Bird (45% of the Company's issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares will be transferred within escrow and remain bound by those terms and conditions. The Escrow Transfer is subject to TSX-V approval. INO: 8.10 (+0.13), TPI.VN: 0.415 (-0.025)
IIROC Trade Halt - T-Bird Pharma Inc.
Newsfile Corp - Wed Mar 11, 11:55AM CDT
The following issues have been halted by IIROC:
IIROC Trading Halt - TPI
CNW Group - Wed Mar 11, 11:52AM CDT
The following issues have been halted by IIROC:
TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Announces License Renewal from Health Canada
CNW Group - Tue Feb 10, 6:00AM CST
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", wishes to announce that its wholly owned subsidiary Thunderbird Biomedical Inc. has received a notice from Health Canada dated February 6, 2015 confirming the renewal of its production license at the Company's production facility in Saanich, British Columbia. TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Appoints Sandy Pratt as Chief Financial Officer
CNW Group - Tue Jan 27, 6:00AM CST
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", wishes to announce that Sandra (Sandy) Pratt has joined the Company as Chief Financial Officer, replacing Chris Taylor who has stepped down to return to his private practice. Taylor will remain involved with the Company at the Board level by continuing on as Corporate Secretary and operationally as an RPIC and consultant. "Chris' background in our history and operations is valuable so we are very pleased to see that he has agreed to remain involved with the Company at the Board level" noted David Raffa, Chairman of the Board. Added Raffa, "the addition of Sandy to our team represents another step in increasing the operational experience within our company as we commercialize our operation. We are very pleased she has agreed to join our team." TPI.VN: 0.415 (-0.025)
T-Bird Pharma Inc. Appoints Dr. Bin Huang as Chief Executive Officer
CNW Group - Mon Jan 19, 5:00AM CST
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR", wishes to announce that Robert Gagnon has stepped down as CEO and Board member. Dr. Bin Huang, who joined the Company last Fall as President and Chief Operating Officer, has been appointed CEO in his place. Noted Gagnon, "Now that the Company is launched and we have brought in professional management, it is time for me to step aside. I am confident in Dr. Huang and the team she is building and pleased that she has agreed to lead the next stage of our growth." Gagnon will be retained by the Company as a consultant for a period of one year. TPI.VN: 0.415 (-0.025)
